105 Results for "

GNE

" in MedChemExpress (MCE) Product Catalog:
Products (105)

105 Results for "GNE" in MCE Product Catalog:

20
20 Publications Verification
Cat. No.: HY-100742A
CAS No.: 2003234-63-5
Purity:  99.73%
(R)-GNE-140 is a potent inhibitor of lactate dehydrogenase (LDH) A, B and C, with IC50 values of 3, 5 and 5 nM against LDHA, LDHB, LDHC, respectively. (R)-GNE-140 blocks the conversion of pyruvate to lactate, reduces lactate production and histone lysine lactylation, and inhibits glycolysis. (R)-GNE-140 attenuates cardiac hypertrophy, alleviates PM2.5-induced pulmonary inflammation and fibrosis, blocks MRSA-induced Arg1 expression. (R)-GNE-140 is applicable to research related to pathological cardiac hypertrophy, pulmonary fibrosis, MRSA infection and pancreatic cancer .
loading...
    loading...
13
13 Cited Publications
Cat. No.: HY-13246
CAS No.: 1032754-93-0
Purity:  99.29%
Synonyms: GDC-0980; GNE 390; RG 7422
Target:  

PI3K mTOR Apoptosis

Research Areas:  

Cancer

Apitolisib (GDC-0980; GNE 390; RG 7422) is a selective, potent, orally bioavailable Class I PI3 kinase and mTOR kinase (TORC1/2) inhibitor with IC50s of 5 nM/27 nM/7 nM/14 nM for PI3Kα/PI3Kβ/PI3Kδ/PI3Kγ, and with a?Ki?of 17 nM for mTOR.
loading...
    loading...
11
11 Cited Publications
Cat. No.: HY-12947
CAS No.: 1496581-76-0
Purity:  99.54%
Target:  

MAP3K

Research Areas:  

Neurological Disease

GNE-3511 is an orally active bioavailable and brain-penetrant dual leucine zipper kinase (DLK) inhibitor with a Ki of 0.5 nM. GNE-3511 can cross the blood-brain-barrier and can be used for the research of neurodegenerative diseases .
loading...
    loading...
11
11 Cited Publications
Cat. No.: HY-100343
CAS No.: 1449277-10-4
Purity:  99.49%
Target:  

MAP4K

Research Areas:  

Cancer

GNE-495 is a potent and selective MAP4K4 inhibitor with an IC50 of 3.7 nM.
loading...
    loading...
9
9 Cited Publications
Cat. No.: HY-100742
CAS No.: 1802977-61-2
Purity:  99.38%
Target:  

Lactate Dehydrogenase

Research Areas:  

Cancer

GNE-140 racemate (Compound 28) is an external racemization mixture of (R)-GNE-140 (HY-100742A) and (S)-GNE-140 (HY-100742B), and it is also an interconformational isomer of GNE-140 (HY-118241). GNE-140 racemate is also an effective lactate dehydrogenase (LDH) inhibitor, with the IC50 values for LDHA and LDHB being 9 nM and 30 nM respectively. GNE-140 racemate can be used in cancer research .
loading...
    loading...
8
8 Cited Publications
Cat. No.: HY-112937
CAS No.: 2009273-67-8
Purity:  99.91%
Target:  

Deubiquitinase

Research Areas:  

Cancer

GNE-6640 is a selective and non-covalent inhibitor of ubiquitin epecific peptidase 7 (USP7), with IC50 values of 0.75 μM, 0.43 μM, 20.3 μM and 0.23 μM for full length USP7, USP7 catalytic domain, full length USP47 and Ub-MDM2, respectively .
loading...
    loading...
7
7 Cited Publications
Cat. No.: HY-108435
CAS No.: 1936421-41-8
Purity:  98.01%
GNE-049 is a highly potent and selective CBP inhibitor with an IC50 of 1.1 nM in TR-FRET assay. GNE-049 also inhibits BRET and BRD4(1) with IC50s of 12 nM and 4200 nM, respectively .
loading...
    loading...
7
7 Cited Publications
Cat. No.: HY-107986
CAS No.: 2009273-71-4
Purity:  98.01%
Target:  

Deubiquitinase

Research Areas:  

Cancer

GNE-6776 is a selective and orally bioavailable USP7 inhibitor .
loading...
    loading...
7
7 Cited Publications
Cat. No.: HY-15766
CAS No.: 1362154-70-8
Purity:  99.58%
Target:  

NAMPT

Research Areas:  

Metabolic Disease Cancer

GNE-617 is a specific NAMPT inhibitor that inhibits the biochemical activity of NAMPT with an IC50 of 5 nM and exhibits efficacy in xenograft models of cancer.
loading...
    loading...
7
7 Cited Publications
Cat. No.: HY-15766A
CAS No.: 2070014-99-0
Purity:  99.16%
Target:  

NAMPT

Research Areas:  

Cancer

GNE-617 hydrochloride is a specific NAMPT inhibitor that inhibits the biochemical activity of NAMPT with an IC50 of 5 nM and exhibits efficacy in xenograft models of cancer.
loading...
    loading...
6
6 Cited Publications
Cat. No.: HY-147214
CAS No.: 2648450-42-2
Purity:  99.54%
Target:  

YAP

Research Areas:  

Cancer

GNE-7883 is a pan-TEAD inhibitor that blocks the association of YAP/TAZ with TEAD. GNE-7883 effectively reduces chromatin accessibility at TEAD motifs, inhibits cell proliferation in multiple cell line models, and achieves strong anti-tumor efficacy in vivo. In addition, GNE-7883 effectively overcomes intrinsic and acquired resistance to KRAS (Kirsten rat sarcoma viral oncogene homolog) G12C inhibitors in multiple preclinical models by inhibiting YAP/TAZ activation .
loading...
    loading...
6
6 Cited Publications
Cat. No.: HY-108696
CAS No.: 1936422-33-1
Purity:  98.16%
GNE-781 is an orally active, highly potent and selective CBP inhibitor with an IC50 of 0.94 nM in TR-FRET assay. GNE-781 also inhibits BRET and BRD4(1) with IC50s of 6.2 nM and 5100 nM, respectively. GNE-781 displays antitumor activity in an MOLM-16 AML xenograft model .
loading...
    loading...
6
6 Cited Publications
Cat. No.: HY-18163
CAS No.: 1351761-44-8
Target:  

LRRK2

Research Areas:  

Neurological Disease

GNE-7915 is a potent, selective and brain-penetrant inhibitor of LRRK2 with an IC50 of 9 nM.
loading...
    loading...
6
6 Cited Publications
Cat. No.: HY-18163A
CAS No.: 2070015-00-6
Target:  

LRRK2

Research Areas:  

Neurological Disease

GNE-7915 tosylate is a potent, selective and brain-penetrant inhibitor of LRRK2 with an IC50 of 9 nM.
loading...
    loading...
5
5 Cited Publications
Cat. No.: HY-100726
CAS No.: 1936428-93-1
Purity:  99.60%
GNE-272 is a potent and selective CBP/EP300 inhibitor with IC50 values of 0.02, 0.03 and 13 μM for CBP, EP300 and BRD4, respectively. GNE-272 is also a selective in vivo probe for CBP/EP300 .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-10811
CAS No.: 1033735-94-2
Purity:  99.81%
Target:  

PI3K mTOR

Research Areas:  

Cancer

GNE-493 is a potent, selective, and orally available dual pan-PI3-kinase/mTOR inhibitor with IC50s of 3.4 nM, 12 nM, 16 nM, 16 nM and 32 nM for PI3Kα, PI3Kβ, PI3Kδ, PI3Kγ and mTOR.
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-135892
CAS No.: 2680616-96-8
Purity:  99.23%
Target:  

MAP4K

Research Areas:  

Inflammation/Immunology

GNE-1858 is a potent and ATP-competitive hematopoietic progenitor kinase-1 (HPK1) inhibitor, with IC50s of 1.9 nM, 1.9 nM, and 4.5 nM for wild-type and the active mimetic mutants HPK1-TSEE and HPK1-SA, respectively .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-15796
CAS No.: 1374828-69-9
Purity:  99.81%
Target:  

LRRK2

Research Areas:  

Neurological Disease

GNE0877 is a highly selective, orally active and brain-penetrant LRRK2 inhibitor with an IC50 of 3 nM and a Ki of 0.7 nM. GNE0877 can be used for the research of neuroscience .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-12632
CAS No.: 1394121-05-1
Purity:  99.16%
Target:  

PAK

Research Areas:  

Cancer

GNE 2861 is a PAK inhibitor that displays group II selectivity. GNE 2861 inhibits PAK4, PAK5 and PAK6 with IC50s of 7.5, 36, 126 nM, respectively.
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-12628
CAS No.: 1362151-42-5
Purity:  99.89%
Target:  

NAMPT

Research Areas:  

Cancer

GNE-618 is a potent, orally active nicotinamide phosphoribosyl transferase (NAMPT) inhibitor with an IC50 of 6 nM. GNE-618 depletes NAD levels and induces tumor cell death. Anti-tumor activity .
loading...
    loading...